Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor: Systemic review and Meta-analysis

Xiao Su, Mario E. Lacouture, Yuxia Jia, Shenhong Wu

Research output: Contribution to journalReview article

48 Citations (Scopus)

Abstract

Background: Cetuximab, a chimeric antibody against epidermal growth factor receptor has emerged as an effective therapy for advanced colorectal cancer (CRC) and head-neck cancer. However, severe skin toxicity may limit its use. Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash. Methods: Databases Medline (OVID 1998 to July 2008), Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences from 2004 through July 2008 were searched to identify relevant studies. Eligible studies include phase II and III clinical trials in which patients were treated with a single agent, i.e. cetuximab at 400 mg/m2 as initial dose followed by 250 mg/m2 weekly. Incidence, relative risk (RR), and 95% confidence intervals (CI) were calculated using a fixed-effects or random-effects model based on the heterogeneity of included studies. Results: A total of 2,037 patients with a variety of solid tumors from 16 trials were included for analysis. The overall incidence of all-grade skin rash was 88.2% (95% CI: 84.8-91.0%), with11.3% (95% CI: 8.8-14.3%) being high-grade (grade 3 or above). The overall incidence of all-grade acne-like skin rash was 81.6% (95% CI: 75.4-86.6%) with 6.5% (95% CI: 4.1-10.0%) being high-grade. Notably, patients with CRC exhibited a significantly higher incidence of high-grade skin rash (12.6%, 95% CI: 9.7-16.4%) than those with non-CRC (6.6%, 95% CI: 3.6-11.8%) with a risk ratio of 1.9 (95% CI: 1.0-3.6, p = 0.049). From randomized controlled studies, patients who received cetuximab had a significantly increased risk of developing high-grade skin rash in comparison with controls (RR 21.8, 95% CI: 6.9-68.8, p < 0.001). Conclusion: Cancer patients who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in patients with CRC. Further studies are strongly recommended for the prevention and treatment of high-grade skin rash.

Original languageEnglish (US)
Pages (from-to)124-133
Number of pages10
JournalOncology
Volume77
Issue number2
DOIs
StatePublished - Aug 1 2008

Fingerprint

Exanthema
Epidermal Growth Factor Receptor
Meta-Analysis
Confidence Intervals
Antibodies
Neoplasms
Incidence
Colorectal Neoplasms
Head and Neck Neoplasms
Cetuximab
Phase III Clinical Trials
Phase II Clinical Trials
Acne Vulgaris
Odds Ratio
Clinical Trials
Databases
Skin
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{3f8e17f252d14ce7a5c96e36afa6ea2d,
title = "Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor: Systemic review and Meta-analysis",
abstract = "Background: Cetuximab, a chimeric antibody against epidermal growth factor receptor has emerged as an effective therapy for advanced colorectal cancer (CRC) and head-neck cancer. However, severe skin toxicity may limit its use. Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash. Methods: Databases Medline (OVID 1998 to July 2008), Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences from 2004 through July 2008 were searched to identify relevant studies. Eligible studies include phase II and III clinical trials in which patients were treated with a single agent, i.e. cetuximab at 400 mg/m2 as initial dose followed by 250 mg/m2 weekly. Incidence, relative risk (RR), and 95{\%} confidence intervals (CI) were calculated using a fixed-effects or random-effects model based on the heterogeneity of included studies. Results: A total of 2,037 patients with a variety of solid tumors from 16 trials were included for analysis. The overall incidence of all-grade skin rash was 88.2{\%} (95{\%} CI: 84.8-91.0{\%}), with11.3{\%} (95{\%} CI: 8.8-14.3{\%}) being high-grade (grade 3 or above). The overall incidence of all-grade acne-like skin rash was 81.6{\%} (95{\%} CI: 75.4-86.6{\%}) with 6.5{\%} (95{\%} CI: 4.1-10.0{\%}) being high-grade. Notably, patients with CRC exhibited a significantly higher incidence of high-grade skin rash (12.6{\%}, 95{\%} CI: 9.7-16.4{\%}) than those with non-CRC (6.6{\%}, 95{\%} CI: 3.6-11.8{\%}) with a risk ratio of 1.9 (95{\%} CI: 1.0-3.6, p = 0.049). From randomized controlled studies, patients who received cetuximab had a significantly increased risk of developing high-grade skin rash in comparison with controls (RR 21.8, 95{\%} CI: 6.9-68.8, p < 0.001). Conclusion: Cancer patients who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in patients with CRC. Further studies are strongly recommended for the prevention and treatment of high-grade skin rash.",
author = "Xiao Su and Lacouture, {Mario E.} and Yuxia Jia and Shenhong Wu",
year = "2008",
month = "8",
day = "1",
doi = "10.1159/000229752",
language = "English (US)",
volume = "77",
pages = "124--133",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor : Systemic review and Meta-analysis. / Su, Xiao; Lacouture, Mario E.; Jia, Yuxia; Wu, Shenhong.

In: Oncology, Vol. 77, No. 2, 01.08.2008, p. 124-133.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Risk of High-grade skin rash in cancer patients treated with cetuximab - An antibody against epidermal growth factor receptor

T2 - Systemic review and Meta-analysis

AU - Su, Xiao

AU - Lacouture, Mario E.

AU - Jia, Yuxia

AU - Wu, Shenhong

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Background: Cetuximab, a chimeric antibody against epidermal growth factor receptor has emerged as an effective therapy for advanced colorectal cancer (CRC) and head-neck cancer. However, severe skin toxicity may limit its use. Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash. Methods: Databases Medline (OVID 1998 to July 2008), Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences from 2004 through July 2008 were searched to identify relevant studies. Eligible studies include phase II and III clinical trials in which patients were treated with a single agent, i.e. cetuximab at 400 mg/m2 as initial dose followed by 250 mg/m2 weekly. Incidence, relative risk (RR), and 95% confidence intervals (CI) were calculated using a fixed-effects or random-effects model based on the heterogeneity of included studies. Results: A total of 2,037 patients with a variety of solid tumors from 16 trials were included for analysis. The overall incidence of all-grade skin rash was 88.2% (95% CI: 84.8-91.0%), with11.3% (95% CI: 8.8-14.3%) being high-grade (grade 3 or above). The overall incidence of all-grade acne-like skin rash was 81.6% (95% CI: 75.4-86.6%) with 6.5% (95% CI: 4.1-10.0%) being high-grade. Notably, patients with CRC exhibited a significantly higher incidence of high-grade skin rash (12.6%, 95% CI: 9.7-16.4%) than those with non-CRC (6.6%, 95% CI: 3.6-11.8%) with a risk ratio of 1.9 (95% CI: 1.0-3.6, p = 0.049). From randomized controlled studies, patients who received cetuximab had a significantly increased risk of developing high-grade skin rash in comparison with controls (RR 21.8, 95% CI: 6.9-68.8, p < 0.001). Conclusion: Cancer patients who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in patients with CRC. Further studies are strongly recommended for the prevention and treatment of high-grade skin rash.

AB - Background: Cetuximab, a chimeric antibody against epidermal growth factor receptor has emerged as an effective therapy for advanced colorectal cancer (CRC) and head-neck cancer. However, severe skin toxicity may limit its use. Its efficacy in the treatment of other cancers is also undergoing extensive investigation. We performed a systemic review and meta-analysis of published clinical trials to quantify the overall incidence and risk of severe skin rash. Methods: Databases Medline (OVID 1998 to July 2008), Web of Science, and abstracts presented at the American Society of Clinical Oncology conferences from 2004 through July 2008 were searched to identify relevant studies. Eligible studies include phase II and III clinical trials in which patients were treated with a single agent, i.e. cetuximab at 400 mg/m2 as initial dose followed by 250 mg/m2 weekly. Incidence, relative risk (RR), and 95% confidence intervals (CI) were calculated using a fixed-effects or random-effects model based on the heterogeneity of included studies. Results: A total of 2,037 patients with a variety of solid tumors from 16 trials were included for analysis. The overall incidence of all-grade skin rash was 88.2% (95% CI: 84.8-91.0%), with11.3% (95% CI: 8.8-14.3%) being high-grade (grade 3 or above). The overall incidence of all-grade acne-like skin rash was 81.6% (95% CI: 75.4-86.6%) with 6.5% (95% CI: 4.1-10.0%) being high-grade. Notably, patients with CRC exhibited a significantly higher incidence of high-grade skin rash (12.6%, 95% CI: 9.7-16.4%) than those with non-CRC (6.6%, 95% CI: 3.6-11.8%) with a risk ratio of 1.9 (95% CI: 1.0-3.6, p = 0.049). From randomized controlled studies, patients who received cetuximab had a significantly increased risk of developing high-grade skin rash in comparison with controls (RR 21.8, 95% CI: 6.9-68.8, p < 0.001). Conclusion: Cancer patients who received cetuximab have a substantial risk of developing high-grade skin rash. The risk may be particularly increased in patients with CRC. Further studies are strongly recommended for the prevention and treatment of high-grade skin rash.

UR - http://www.scopus.com/inward/record.url?scp=67650702948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650702948&partnerID=8YFLogxK

U2 - 10.1159/000229752

DO - 10.1159/000229752

M3 - Review article

C2 - 19622903

AN - SCOPUS:67650702948

VL - 77

SP - 124

EP - 133

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -